Antithrombotic activity of heparin-ATP complex

Оберган, Т.Ю.; Lyapina, L. A.; Pastorova, V. E.

doi:10.1007/s10517-007-0094-y

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional inhibition by P2Y 1 receptor antagonists of platelet aggregation produced by P2Y 12 receptor antagonists has been considered [361,362]. A complex of high molecular weight heparin and ATP prevented thrombus formation [363]. ADP-inducible platelet reactivity ] i responses of rat megakaryocytes to ADP (1 μM, horizontal bar) and step depolarizations from a holding potential of −75 mV.…”

Section: Thrombosismentioning

confidence: 99%

Blood cells: an historical account of the roles of purinergic signalling

Burnstock

2015

Purinergic Signalling

View full text Add to dashboard Cite

The involvement of purinergic signalling in the physiology of erythrocytes, platelets and leukocytes was recognised early. The release of ATP and the expression of purinoceptors and ectonucleotidases on erythrocytes in health and disease are reviewed. The release of ATP and ADP from platelets and the expression and roles of P1, P2Y 1 , P2Y 12 and P2X1 receptors on platelets are described. P2Y 1 and P2X1 receptors mediate changes in platelet shape, while P2Y 12 receptors mediate platelet aggregation. The changes in the role of purinergic signalling in a variety of disease conditions are considered. The successful use of P2Y 12 receptor antagonists, such as clopidogrel and ticagrelor, for the treatment of thrombosis, myocardial infarction and stroke is discussed.

show abstract

Section: Thrombosismentioning

confidence: 99%

Blood cells: an historical account of the roles of purinergic signalling

Burnstock

2015

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…It is not widely known that UFH regulates the ATP effects, forming complexes with ATP that have anticoagulant properties and prevent thrombogenesis in the bloodstream [ 22 ]. At the same time, heparin is a selective inhibitor of inositol-1,4,5-triphosphate receptors involved in the process of ATP-dependent Ca 2+ flow into the cell; it is able to inhibit coagulation factors at the initial stage of activation, reducing the level of intracellular Ca 2+ [ 23 ].…”

Section: Covid-19-associated Coagulopathy and Mechanisms Of Heparin A...mentioning

confidence: 99%

Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases

Kondashevskaya

2022

J Evol Biochem Phys

View full text Add to dashboard Cite

The disease caused by the coronavirus SARS-CoV-2, named COVID-19, has been spread around the world at a high transmission rate. It was initially considered to be an acute respiratory distress syndrome. Recent clinical data has highlighted that COVID-19 is characterized by a vascular dysfunction and thrombosis, which are not typical for many other acute respiratory diseases. Thrombotic complications are markers of severe COVID-19 and are associated with multiple organ failure and increased mortality. The application of unfractionated and/or low-molecular-weight heparins as anticoagulant medications, significantly reduced the severity of the disease and COVID-19-induced mortality, since heparin is a multifunctional agent. The goal of this review is to summarize the literature data on the pathogenic mechanisms of SARS-CoV-2 and to characterize the properties of heparin, which allow inhibiting these mechanisms at any stage of pathogenesis. We proposed a vicious circle hypothesis of SARS-CoV-2 pathogenesis, as well as an original approach to low-dose heparin therapy beyond its anticoagulant properties. The analysis of a wide range of effects and mechanisms of action of heparin will help create an idea of current possibilities and future potential of applying this drug.

show abstract

“…Anticoagulant effect of ATP were demonstrated in vitro and in vivo by computer modeling and in experimental coagulation studies [5,6,8]. Another blood anticoagulant, heparin, is present in the vascular endothelium and blood, is highly reactive to the formation of complexes with various substances [10], including ATP [5].…”

mentioning

confidence: 99%

Anticoagulant activity and platelet aggregation in blood plasma from rats after intranasal administration of adenosine triphosphate and its complex with heparin

et al. 2008

Self Cite

View full text Add to dashboard Cite

Fourfold intranasal administration of ATP was followed by an increase in anticoagulant activity and decrease in platelet aggregation in blood plasma of healthy rats and, particularly, of animals with suppressed function of the anticoagulant system. These changes decrease the risk of the prethrombotic state. Complex of ATP and high-molecular-weight heparin decreased platelet aggregation only in the blood from healthy animals, but increased anticoagulant potential of plasma hemostasis in prethrombotic animals.

show abstract

Antithrombotic activity of heparin-ATP complex

Cited by 3 publications

References 6 publications

Blood cells: an historical account of the roles of purinergic signalling

Blood cells: an historical account of the roles of purinergic signalling

Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases

Anticoagulant activity and platelet aggregation in blood plasma from rats after intranasal administration of adenosine triphosphate and its complex with heparin

Contact Info

Product

Resources

About